144 related articles for article (PubMed ID: 4075672)
1. Evaluation of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients.
Ramanna L; Waxman AD; Brachman MB; Tanasescu DE; Sensel N; Braunstein GD
Clin Nucl Med; 1985 Nov; 10(11):791-5. PubMed ID: 4075672
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of low-dose iodine-131 ablation of post-operative thyroid remnants: a study of 69 cases.
Leung SF; Law MW; Ho SK
Br J Radiol; 1992 Oct; 65(778):905-9. PubMed ID: 1422665
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of low doses of I-131 for thyroid ablation in postsurgical patients with thyroid carcinoma.
Siddiqui AR; Edmondson J; Wellman HN; Hamaker RC; Lingeman RE; Park HM; Johnston CC
Clin Nucl Med; 1981 Apr; 6(4):158-61. PubMed ID: 7214770
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
Bal CS; Kumar A; Pant GS
J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
[TBL] [Abstract][Full Text] [Related]
5. Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate, and high activities of radioiodine.
Kusacic Kuna S; Samardzic T; Tesic V; Medvedec M; Kuna K; Bracic I; Despot M; Dodig D
Nucl Med Commun; 2009 Apr; 30(4):263-9. PubMed ID: 19247212
[TBL] [Abstract][Full Text] [Related]
6. The significance of 1-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication.
Waxman A; Ramanna L; Chapman N; Chapman D; Brachman M; Tanasescu D; Berman D; Catz B; Braunstein G
J Nucl Med; 1981 Oct; 22(10):861-5. PubMed ID: 7288483
[TBL] [Abstract][Full Text] [Related]
7. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET.
O'Connell ME; Flower MA; Hinton PJ; Harmer CL; McCready VR
Radiother Oncol; 1993 Jul; 28(1):16-26. PubMed ID: 8234866
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine therapy for differentiated thyroid carcinoma.
Connor CS; Thomas JH; Robinson RG; Preston DF; Hermreck AS
Am J Surg; 1988 Dec; 156(6):519-21. PubMed ID: 3202264
[TBL] [Abstract][Full Text] [Related]
9. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
[TBL] [Abstract][Full Text] [Related]
10. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
Silberstein EB
J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
[TBL] [Abstract][Full Text] [Related]
11. Treatment rationale in thyroid carcinoma. Effect of scan dose.
Ramanna L; Waxman AD; Brachman MB; Tanasescu DE; Chapman N; Braunstein GD
Clin Nucl Med; 1985 Oct; 10(10):687-9. PubMed ID: 4075650
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the efficacy of iodine-131 for thyroid ablation.
Comtois R; Thériault C; Del Vecchio P
J Nucl Med; 1993 Nov; 34(11):1927-30. PubMed ID: 8229236
[TBL] [Abstract][Full Text] [Related]
13. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
14. [Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer].
Gawkowska-Suwińska M; Turska M; Roskosz J; Puch Z; Jurecka-Tuleja B; Handkiewicz-Junak D; Wygoda Z; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():278-88. PubMed ID: 12182036
[TBL] [Abstract][Full Text] [Related]
15. [Long-term course in differentiated thyroid gland carcinoma].
Rösler H; Birrer A; Lüscher D; Kinser J
Schweiz Med Wochenschr; 1992 Nov; 122(48):1843-57. PubMed ID: 1462145
[TBL] [Abstract][Full Text] [Related]
16. Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer.
McCowen KD; Adler RA; Ghaed N; Verdon T; Hofeldt FD
Am J Med; 1976 Jul; 61(1):52-8. PubMed ID: 937370
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
Zaman Mu; Toor R; Kamal S; Maqbool M; Habib S; Niaz K
J Pak Med Assoc; 2006 Aug; 56(8):353-6. PubMed ID: 16967785
[TBL] [Abstract][Full Text] [Related]
18. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine therapy of thyroid disease.
Beierwaltes WH
Int J Rad Appl Instrum B; 1987; 14(3):177-81. PubMed ID: 3312117
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients.
Maxon HR; Englaro EE; Thomas SR; Hertzberg VS; Hinnefeld JD; Chen LS; Smith H; Cummings D; Aden MD
J Nucl Med; 1992 Jun; 33(6):1132-6. PubMed ID: 1597728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
